Stefano Piaserico1, Simone Cazzaniga2, Sergio Chimenti3, Alberto Giannetti4, Mara Maccarone5, Mauro Picardo6, Andrea Peserico7, Luigi Naldi2. 1. Dermatology Unit, Department of Medicine, University of Padua, Padua, Italy. Electronic address: stefano.piaserico@unipd.it. 2. Centro Studi Gruppo Italiano Studi In Epidemiologia (GISED), Papa Giovanni XXIII Hospital, Bergamo, Italy. 3. Department of Dermatology, University of Rome "Tor Vergata", Rome, Italy. 4. Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy. 5. Italian Psoriatic Patient Association (Associazione Difesa Pazienti Psoriasici [ADIPSO]), Rome, Italy. 6. Laboratory of Cutaneous Physiopathology, San Gallicano Dermatological Institute Rome, Rome, Italy. 7. Dermatology Unit, Department of Medicine, University of Padua, Padua, Italy.
Abstract
BACKGROUND: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. OBJECTIVE: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. METHODS: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. RESULTS: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and by 45.6% after 24 weeks. Patients who switched because of secondary loss of efficacy (loss of initial PASI 75 response) or adverse events/intolerance were more likely to reach PASI 75 than those who switched as a result of primary inefficacy (PASI 75 never achieved) (hazard ratio 2.7, 95% confidence interval 1.3-5.5 vs hazard ratio 2.0, 95% confidence interval 1.0-3.9 and 1, respectively). LIMITATIONS: There was a small number of patients with complete follow-up data. CONCLUSION: PASI 75 response in patients who switched from one anti-TNF-alfa agent to another was significantly reduced in patients who showed primary inefficacy of the first anti-TNF-alfa.
BACKGROUND: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. OBJECTIVE: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. METHODS: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. RESULTS: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and by 45.6% after 24 weeks. Patients who switched because of secondary loss of efficacy (loss of initial PASI 75 response) or adverse events/intolerance were more likely to reach PASI 75 than those who switched as a result of primary inefficacy (PASI 75 never achieved) (hazard ratio 2.7, 95% confidence interval 1.3-5.5 vs hazard ratio 2.0, 95% confidence interval 1.0-3.9 and 1, respectively). LIMITATIONS: There was a small number of patients with complete follow-up data. CONCLUSION: PASI 75 response in patients who switched from one anti-TNF-alfa agent to another was significantly reduced in patients who showed primary inefficacy of the first anti-TNF-alfa.
Keywords:
75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitors
Authors: Giovanni Damiani; Rosalynn R Z Conic; Valerio de Vita; Antonio Costanzo; Roberto Regazzini; Paolo D M Pigatto; Nicola L Bragazzi; Alessia Pacifico; Piergiorgio Malagoli Journal: Dermatol Ther Date: 2018-12-21 Impact factor: 2.851
Authors: Neal Bhatia; Andrew Blauvelt; Marc Brown; Whitney High; Craig T Leonardi; Ted Rosen; Linda Stein Gold; Eggert Stockfleth; Bruce Strober; Neil A Swanson; George Martin Journal: J Clin Aesthet Dermatol Date: 2014-07
Authors: A Campanati; M Orciani; G Sorgentoni; V Consales; M Mattioli Belmonte; R Di Primio; A Offidani Journal: Clin Exp Immunol Date: 2018-05-31 Impact factor: 4.330
Authors: Sabrina Giometto; Silvia Tillati; Laura Baglietto; Nicola De Bortoli; Marta Mosca; Marco Conte; Marco Tuccori; Rosa Gini; Ersilia Lucenteforte Journal: Int J Environ Res Public Health Date: 2022-06-02 Impact factor: 4.614
Authors: Ji Sun van Bezooijen; Deepak M W Balak; Martijn B A van Doorn; Caspar W N Looman; Marco W J Schreurs; Birgit C P Koch; Teun van Gelder; Errol P Prens Journal: Dermatology Date: 2016-09-01 Impact factor: 5.366
Authors: P Cordiali-Fei; L Bianchi; C Bonifati; E Trento; M Ruzzetti; F Francesconi; S Bultrini; G D'Agosto; V Bordignon; V Francavilla; A Tripiciano; A Chiricozzi; E Campione; C Cavallotti; A Orlandi; E Berardesca; A Di Carlo; S Chimenti; F Ensoli Journal: Mediators Inflamm Date: 2014-07-20 Impact factor: 4.711